What is 4D Molecular Therapeutics's net change in cash?

4D Molecular Therapeutics (FDMT) reported net change in cash of $12.25M in Q1 2026.

How has 4D Molecular Therapeutics's net change in cash changed year-over-year?

4D Molecular Therapeutics's net change in cash increased by 177.5% year-over-year, from -$15.81M to $12.25M.

What does net change in cash mean?

Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.

4D Molecular Therapeutics FDMT Net Change in Cash

Net Change in Cash at other companies

Eli LillyLLY

-$1.99B-1,035%

Regeneron PharmaceuticalsREGN

-$153.1M-125%

Vertex PharmaceuticalsVRTX

$417.1M+268%

EyePoint, Inc. EYPT

-$24.11M-65.7%

AbbVieABBV

$4.16B+1,293%

RegenxbioRGNX

-$19.24M-127%

Other financials

Income statement

See full

Revenue$3.0M+21,664%

Operating income-$73.6M-37.3%

Net income-$68.8M-43.3%

EPS (diluted)-$1.01-17.4%

Balance sheet

See full

Cash & equivalents$72.5M-45.7%

Total debt$20.5M-13.9%

Total equity$451.8M-3.8%

Total assets$512.9M-0.5%

Cash flow

See full

Operating cash flow-$68.1M-42.6%

CapEx--100%

Free cash flow-$68.1M-40.8%

Valuation

See full

Market cap$602.22M+215%

Enterprise value$550.27M+574%

P/S6.8×-8,306×

Profitability

See full

Operating margin-220.1%-110pp

Net margin-174,314.2%-62,763pp

FCF margin-154,209.2%-53,057pp

Returns & leverage

See full

Return on equity-45.4%+29.8pp

Debt / equity0×0.0×

Current ratio9.3×-3.0×

Where this comes from

Reported directly by 4D Molecular Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about 4D Molecular Therapeutics's net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is 4D Molecular Therapeutics's net change in cash?: 4D Molecular Therapeutics (FDMT) reported net change in cash of $12.25M in Q1 2026.
How has 4D Molecular Therapeutics's net change in cash changed year-over-year?: 4D Molecular Therapeutics's net change in cash increased by 177.5% year-over-year, from -$15.81M to $12.25M.
What does net change in cash mean?: Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.